38090813|t|Discovery of Orally Available and Brain Penetrant AEP Inhibitors.
38090813|a|Alzheimer's Disease (AD) is the most widespread form of dementia, with one of the pathological hallmarks being the formation of neurofibrillary tangles (NFTs). These tangles consist of phosphorylated Tau fragments. Asparagine endopeptidase (AEP) is a key Tau cleaving enzyme that generates aggregation-prone Tau fragments. Inhibition of AEP to reduce the level of toxic Tau fragment formation could represent a promising therapeutic strategy. Here, we report the first orthosteric, selective, orally bioavailable, and brain penetrant inhibitors with an irreversible binding mode. We outline the development of the series starting from reversible molecules and demonstrate the link between inhibition of AEP and reduction of Tau N368 fragment both in vitro and in vivo.
38090813	50	53	AEP	Gene	5641
38090813	66	85	Alzheimer's Disease	Disease	MESH:D000544
38090813	87	89	AD	Disease	MESH:D000544
38090813	122	130	dementia	Disease	MESH:D003704
38090813	194	217	neurofibrillary tangles	Disease	MESH:D055956
38090813	219	223	NFTs	Disease	MESH:D055956
38090813	232	239	tangles	Disease	MESH:D055956
38090813	266	269	Tau	Gene	4137
38090813	281	305	Asparagine endopeptidase	Gene	5641
38090813	307	310	AEP	Gene	5641
38090813	321	324	Tau	Gene	4137
38090813	374	377	Tau	Gene	4137
38090813	403	406	AEP	Gene	5641
38090813	436	439	Tau	Gene	4137
38090813	769	772	AEP	Gene	5641
38090813	790	793	Tau	Gene	4137
38090813	Positive_Correlation	4137	5641
38090813	Association	MESH:D055956	4137
38090813	Association	MESH:D000544	5641

